3α-Hydroxy-17β-(N-methylamino)-5α-androstane | 115016-02-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3α-Hydroxy-17β-(N-methylamino)-5α-androstane
• 英文别名: 3α-hydroxy-17β-methylamino-5α-androstane；(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(methylamino)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 115016-02-9
• 化学式: C₂₀H₃₅NO
• 分子量: 305.504
• InChiKey: LXUIGQVHABEBDW-RGJFDMQWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  17β-formamido-5α-androstan-3α-ol 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以85%的产率得到3α-Hydroxy-17β-(N-methylamino)-5α-androstane
  参考文献：
  名称：

  差向异构 17-amino-5?-androstan-3-ols 及其衍生物的合成及抗心律失常活性

  摘要：

  一些不具有激素特性的甾体胺具有抗心律失常、降血压或强心作用 [3, 6, 9]。Campbell 和 Williams [5] 推荐使用 3=-amino-5=-androstan-28-ol-17-one 治疗心律失常。我们现在已经从自制的植物材料中合成了一些容易获得的、更简单的 5asteroid，即 17-amino-5-a-androstan-3-ols (I-IV)，它们在 C(3) 和 C(7) 处是差向异构的, 并检查了它们的抗心律失常活性~ 38, 178 差向异构体 (I) 显示出最大的活性，它被用来获得一系列 N-烷基和 N-氨酰基衍生物。

  DOI：

  10.1007/bf00758270

文献信息

• Therapeutic treatment methods 2
  申请人：Reading L. Christopher

  公开号：US20050101581A1

  公开（公告）日：2005-05-12

  The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

  本发明涉及使用化合物来改善或治疗诸如囊性纤维化、中性粒细胞减少症或其他示例性疾病。可使用的示例化合物包括 3β-羟基-17β-氨基雄甾-5-烯、3β-羟基-16α-氟-17β-氨基雄甾-5-烯、3α-羟基-16α-氟-17β-氨基雄甾-5-烯、3β-羟基-16β-氟-17β-氨基雄甾-5-烯、1α,3β-二羟基-4α-氟-雄甾-5-烯-17-酮、1α,3β,17β-三羟基-4α-氟雄甾烷-5-烯、1β,3β-二羟基-6α-溴雄甾烷-5-烯、1α-氟-3β,12α-二羟基雄甾烷-5-烯-17-酮、1α-氟-3β,4α-二羟基雄甾烷-5-烯和 4α-氟-3β,6α,17β-三羟基雄甾烷。
• NADARAJA, N. SH.;SLADKOV, V. I.;DORODNIKOVA, E. V.;MASHKOVSKIJ, M. D.;KEM+, XIM.-FARMATS. ZH., 22,(1988) N 3, 288-293
  作者：NADARAJA, N. SH.、SLADKOV, V. I.、DORODNIKOVA, E. V.、MASHKOVSKIJ, M. D.、KEM+

  DOI：——

  日期：——
• Sepsis Treatment Methods
  申请人：Reading L. Christopher

  公开号：US20070213309A1

  公开（公告）日：2007-09-13

  The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3η-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
• Asthma Treatment Methods
  申请人：Reading L. Christopher

  公开号：US20070265236A1

  公开（公告）日：2007-11-15

  The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
• Therapeutic Treatment Methods
  申请人：Reading L. Christopher

  公开号：US20070275937A1

  公开（公告）日：2007-11-29

  The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.